UMoleac umemezele ukukhululwa kwemiphumela yocwaningo lwe-ATHENE, eshicilelwe ku-Journal of the American Medical Director Association (JAMDA).
Imithi yokwelapha engase ibambezele ngempumelelo i-AD uma isifinyelele esigabeni somtholampilo, ihlala iyisidingo sezokwelapha esibalulekile esingakafinyelelwa. I-NeuroAiD™II ibonise ukuthi inemiphumela yokumodulatory ku-amyloid precursor protein (APP) processing2 kanye nokuguqulwa kweprotheyini ye-tau ibe amafomu angavamile we-phosphorylated kanye ne-aggregated3, kanye nezakhiwo ze-neuro-regenerative kanye ne-neuro-restorative4. Imiphumela enenzuzo ye-NeuroAiD™II emisebenzini yokuqonda ekhubazekile isivele ikhonjisiwe ekulimaleni kobuchopho okubuhlungu5.
Ucwaningo lwe-Alzheimer's Therapy with NEuraiid (ATHENE) luwucwaningo lokuqala lokuhlola ukuphepha nokusebenza ngempumelelo kwe-NeuroAiD™II ezigulini ze-AD ezithambile kuya kwezimaphakathi ezizinzile ekwelashweni okujwayelekile kwezimpawu.
I-ATHENE kwakuyisivivinyo sezinyanga ezingu-6 esingahleliwe esingahleliwe esingaboni kahle, esilawulwa yi-placebo esilandelwa isandiso selebula evulekile yokwelashwa kwe-NeuroAiD™II kwezinye izinyanga ze-6. Izifundo ze-125 ezivela eSingapore zafakwa ocwaningweni, olwahlanganiswa yiMemory Aging and Cognition Centre, National University Health System, National Neuroscience Institute, kanye neSt. Luke's Hospital, Singapore.
• I-NeuroAiD™II ibonise ukuphepha kwesikhathi eside njengokwelashwa okungeziwe ku-AD ngaphandle kokunyuka kweziguli ezihlangabezana nezenzakalo ezimbi ezimbi noma izehlakalo ezimbi.
• Ukuqaliswa kwangaphambi kwesikhathi kwe-NeuroAiD™II kunikeze ukuthuthukiswa kwesikhathi eside kokuqaphela uma kuqhathaniswa ne-placebo (iqembu labaqalayo sekwephuzile) elilinganiswa nge-ADAS-cog, ebaluleke ngokwezibalo ezinyangeni ezingu-9, futhi yehlisa ukwehla ngokuhamba kwesikhathi.
Imiphumela yocwaningo lwe-ATHENE isekela ukuhlomula kwe-NeuroAiD™II njengokwelashwa okungeziwe okuphephile ekwelapheni okujwayelekile kwe-AD njengoba ucwaningo abutholanga ubufakazi bokwenyuka okuphawulekayo kwezehlakalo ezimbi phakathi kwe-MLC901 ne-placebo. Ukuhlaziya kuphakamisa amandla e-MLC901 ekwehliseni isivinini sokuqhubekela phambili kwe-AD okuhambisana nezifundo zangaphambi kweklinikhi nezomtholampilo ezishicilelwe ngaphambilini, okuyenza ibe yindlela yokwelapha ethembisayo ezigulini ze-AD. Le miphumela idinga ukuqinisekiswa okwengeziwe ezifundweni ezinkulu nezinde.
Izwi elivela kuMseshi Omkhulu
“Isifo i-Alzheimer’s yisona esivame ukubangela ukuwohloka komqondo, okubalelwa ku-60-80% wamacala. Kuze kube yilapho sekugunyazwa kwakamuva kwe-aducanumab yi-FDA, bekungekho ukwelashwa okuguqula isifo kwe-Alzheimer's, futhi izindlela zokwelapha ezinezimpawu ezitholakalayo njengamanje zifuna ukubambezela okwesikhashana ukuwohloka komqondo okuwohlokayo kanye nokwenza ngcono izinga lempilo yalabo abane-Alzheimer kanye nabanakekeli babo. Ngakho-ke, kunesidingo sokunikeza iziguli kanye nabanakekeli bazo ukufinyelela kusenesikhathi ekuxilongweni nasekulashweni okusha.
Imiphumela ethembisayo yocwaningo lwe-ATHENE kufanele iqondwe njengengxenye yepayipi lokuthuthukiswa kwezidakamizwa ze-Alzheimer's Disease ukusuka ekubeni nezimpawu kuya ekwelashweni kokuguqula izifo. Lolu cwaningo nezinye izindlela zokwelapha ezingase zibe khona kufanele zihlolwe ngokuqinile ngokuhlolwa komtholampilo okuklanywe kahle.”
UProfesa Christopher Chen
Umqondisi, iMemory Aging and Cognition Centre, iNational University Health System kanye noProfesa Ohlangene, uMnyango Wezemithi, i-Yong Loo Lin School of Medicine, iNyuvesi Kazwelonke yaseSingapore.
